US-based Theravance Biopharma has started a Phase I clinical trial of TD-1473, a potent, orally administered GI-targeted pan-Janus kinase (JAK) inhibitor, to treat inflammatory intestinal diseases.

TD-1473 is an internally discovered JAK inhibitor that has showed a high affinity for each of the JAK family of enzymes: JAK1, JAK2, JAK3 and TYK2.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

In inhibiting these enzymes, TD-1473 interferes with the JAK / STAT signaling pathway, and modulates the activity of a range of pro-inflammatory cytokines.

"Our targeted approach seeks to maximise the therapeutic potential of JAK inhibition."

TD-1473 is primarily a GI-targeted treatment, designed to be distributed adequately and exclusively to GI tract tissues, and minimise systemic exposure.

The primary objective of the Phase I trial is to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of TD-1473 in healthy subjects.

See Also:

The trial’s secondary objective will be the characterisation of pharmacokinetics related to TD-1473, which will help determine the amount of TD-1473 that enters systemic circulation after administration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Theravance Research and Development senior vice-president Mathai Mammen said: "In the past month we have advanced two novel, potentially best-in-class programmes from our internal discovery and research engine into Phase I clinical trials.

"Our targeted approach seeks to maximise the therapeutic potential of JAK inhibition in the affected areas of the gastrointestinal tract, while minimising the safety and tolerability concerns associated with systemic JAK blockade.

"Our ability to create a pan-JAK inhibitor that is targeted specifically to the GI tract may enable us to offer patients with ulcerative colitis and other inflammatory intestinal diseases a treatment option that significantly improves upon currently available therapeutics."

Findings from a preclinical trial evaluating TD-1473 and tofacitinib showed that both compounds significantly reduced colitis manifestations.